Mark Peterson

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

Riot Platforms' latest update shows more than mining numbers; it reveals a strategic shift using Bitcoin to fund a major pivot into AI data centers.

Lion Group is diversifying its crypto-heavy treasury with Bitcoin. Is this a savvy move in a cool market or a high-stakes bet for a volatile company?

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.

As the MASH market shifts beyond monotherapy, Galmed's new patent for a combo with Rezdiffra is a strategic move to own a piece of the next-gen solution.

Heron Therapeutics' APONVIE just got a major endorsement. How this single guideline change could reshape patient recovery and shake up the anti-nausea market.

With a $44M war chest and a key crypto acquisition, Thumzup is ditching social media for blockchain and AI. A bold market disruption in the making.

Citius Oncology's partnership with Er-Kim is more than a distribution deal; it's a strategic masterclass in bringing hope to underserved patients.

As GPS jamming cripples drones on the battlefield, AeroVironment’s new visual navigation system for its Puma fleet marks a critical strategic shift.

Display giant AUO is building a powerful smart healthcare ecosystem, using 3D imaging and AI to redefine surgery, diagnostics, and even traditional medicine.

Powersports maker Massimo Group is pivoting into the competitive robotics market. Can its manufacturing DNA overcome financial hurdles and tech giants?

After a turbulent year, Cycurion's $6M private placement signals a major comeback, funding an aggressive push into AI cybersecurity and acquisitions.

Enveric Biosciences heads to J.P. Morgan Week to pitch its novel non-hallucinogenic neuroplastogens. Can it secure the deals to disrupt mental health?

A novel drug aims to replace toxic chemo and conquer aggressive breast cancer. Can Intensity Therapeutics' direct tumor injection shift the treatment paradigm?

Reeling from a trial failure, Neuphoria Therapeutics battles an activist's lowball bid while its board scrambles to unlock hidden value in a high-stakes review.

An Israeli biotech's manufacturing milestone isn't just a production win; it's a strategic move to commercialize its nasal shield technology.

A $3M deal values Eye-Net's V2X tech at $55M, but the complex warrant structure tells a deeper story about Foresight's strategic play in road safety.

Fresh off a massive IPO, MapLight Therapeutics is racing toward pivotal data in schizophrenia and Alzheimer's. Can it defy the odds in biotech's riskiest field?

With nickel prices low, FPX Nickel is doubling down on its own stock. Is this a savvy capital move or a signal of a unique, undervalued asset?

uniQure’s promising gene therapy for Huntington's disease hits a major FDA roadblock, sending its stock tumbling and delaying hope for patients.